Karbamazepin Kullanan Hastalarda Serum Lipid Düzeylerinin Değerlendirilmesi

Abstract

Epilepsy is a neurological disease that requires long-term drug therapy. Carbamazepine (CBZ) is a drug that is effective in partial seizures, including complex partial seizures, and tonic-clonic seizures. It was aimed to evaluate the effect on serum lipid profile in patients who used CBZ. Medical biochemistry laboratory data between January and December 2021 were analyzed retrospectively. Patients (n=59) who used monotherapy and at least 2 years of CBZ were included in the study. Patients under 18 years of age were not included. In the control group, 34 healthy people with normal blood parameters, who applied to outpatient clinics for different reasons at the same age, and did not have a disease that would affect the lipid profile, were selected. The mean age of the patients was 36 ±8 years. LDL-cholesterol levels were found to be higher in patients treated with carbamazepine compared to the control group (p<0.05). There was no significant difference in serum triglyceride (TG), and HDL-cholesterol levels in the patient and control groups (p>0.05). There was no gender difference in the effect of carbamazepine on LDL-cholesterol (p>0.05). High serum LDL-cholesterol levels cause atherosclerosis and coronary artery disease. The lipid profile of carbamazepine, which is used regularly at the therapeutic level, changes. Due to the association of high LDL-cholesterol levels with atherosclerosis, it is important to monitor lipid levels in patients using CBZ, especially considering the long duration of use of this pharmacotherapy.